Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial (2012)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1016/S1470-2045(12)70329-7
- Subjects: NEOPLASIAS MAMÁRIAS (TERAPIA;QUIMIOTERAPIA); ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS); ESTADIAMENTO DE NEOPLASIAS; QUIMIOTERAPIA ADJUVANTE
- Language: Inglês
- Imprenta:
- Source:
- Título: The lancet: oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 13, n. 9, p. 869\2013878, 2012
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ISMAEL, Gustavo et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The lancet: oncology, v. 13, n. 9, p. 869\2013878, 2012Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(12)70329-7. Acesso em: 15 fev. 2026. -
APA
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S. -B., et al. (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The lancet: oncology, 13( 9), 869\2013878. doi:10.1016/S1470-2045(12)70329-7 -
NLM
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial [Internet]. The lancet: oncology. 2012 ; 13( 9): 869\2013878.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1016/S1470-2045(12)70329-7 -
Vancouver
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial [Internet]. The lancet: oncology. 2012 ; 13( 9): 869\2013878.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1016/S1470-2045(12)70329-7 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
Informações sobre o DOI: 10.1016/S1470-2045(12)70329-7 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
